Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.
Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel PS. Nathanson DA, et al. Among authors: masui k. Science. 2014 Jan 3;343(6166):72-6. doi: 10.1126/science.1241328. Epub 2013 Dec 5. Science. 2014. PMID: 24310612 Free PMC article.
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.
Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, Kurdistani SK, Eskin A, Nelson SF, Yong WH, Cavenee WK, Cloughesy TF, Christofk HR, Black DL, Mischel PS. Babic I, et al. Among authors: masui k. Cell Metab. 2013 Jun 4;17(6):1000-1008. doi: 10.1016/j.cmet.2013.04.013. Epub 2013 May 23. Cell Metab. 2013. PMID: 23707073 Free PMC article.
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS. Gini B, et al. Among authors: masui k. Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12. Clin Cancer Res. 2013. PMID: 24030701 Free PMC article.
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.
Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee WK, Shaw RJ, Mischel PS. Masui K, et al. Cell Metab. 2013 Nov 5;18(5):726-39. doi: 10.1016/j.cmet.2013.09.013. Epub 2013 Oct 17. Cell Metab. 2013. PMID: 24140020 Free PMC article.
mTORC2 dictates Warburg effect and drug resistance.
Masui K, Cavenee WK, Mischel PS. Masui K, et al. Cell Cycle. 2014;13(7):1053-4. doi: 10.4161/cc.28377. Epub 2014 Feb 28. Cell Cycle. 2014. PMID: 24583874 Free PMC article. No abstract available.
mTORC2 in the center of cancer metabolic reprogramming.
Masui K, Cavenee WK, Mischel PS. Masui K, et al. Trends Endocrinol Metab. 2014 Jul;25(7):364-73. doi: 10.1016/j.tem.2014.04.002. Epub 2014 May 21. Trends Endocrinol Metab. 2014. PMID: 24856037 Free PMC article.
Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, Mischel PS, Kohmura E. Tanaka K, et al. Among authors: masui k. J Clin Invest. 2015 Apr;125(4):1591-602. doi: 10.1172/JCI78239. Epub 2015 Mar 23. J Clin Invest. 2015. PMID: 25798620 Free PMC article.
410 results